These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37173578)

  • 1. The role of DSC MR perfusion in predicting IDH mutation and 1p19q codeletion status in gliomas: meta-analysis and technical considerations.
    Siakallis L; Topriceanu CC; Panovska-Griffiths J; Bisdas S
    Neuroradiology; 2023 Jul; 65(7):1111-1126. PubMed ID: 37173578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Determination of
    Bhandari AP; Liong R; Koppen J; Murthy SV; Lasocki A
    AJNR Am J Neuroradiol; 2021 Jan; 42(1):94-101. PubMed ID: 33243896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Eur Radiol; 2019 Feb; 29(2):745-758. PubMed ID: 30003316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
    Liu Z; Zhang T; Jiang H; Xu W; Zhang J
    Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network.
    Choi KS; Choi SH; Jeong B
    Neuro Oncol; 2019 Sep; 21(9):1197-1209. PubMed ID: 31127834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma.
    Ma X; Cheng K; Cheng G; Li C; Lyu J; Lan Y; Duan C; Bian X; Zhang J; Lou X
    J Magn Reson Imaging; 2023 Sep; 58(3):732-738. PubMed ID: 36594577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
    Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H
    J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
    Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Key Molecular Markers in Adult Diffuse Gliomas Based on a Novel Combination of Diffusion and Perfusion MRI and MR Spectroscopy.
    Su X; Yang X; Sun H; Liu Y; Chen N; Li S; Huang Z; Shao H; Zhang S; Gong Q; Yue Q
    J Magn Reson Imaging; 2024 Feb; 59(2):628-638. PubMed ID: 37246748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Dynamic Susceptibility Contrast Perfusion Imaging be Utilized to Detect Isocitrate Dehydrogenase Gene Mutation in Gliomas?
    Kilincer A; Cebeci H; Seher N; Durmaz MS; Uysal E; Sahinoglu M; Koktekir E; Karabagli H; Karabagli P; Paksoy Y
    Turk Neurosurg; 2022; 32(5):826-833. PubMed ID: 35713257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.
    Zhao J; Huang Y; Song Y; Xie D; Hu M; Qiu H; Chu J
    Eur Radiol; 2020 Aug; 30(8):4664-4674. PubMed ID: 32193643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.